Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 11/07/23 04:02:00 on US and Canada Markets.
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarter New clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast...
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] PR Newswire Reports Total Revenues of $3.94 Billion ; U.S. GAAP Net Earnings of $332 Million ; Adjus...
SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Upwork Inc. (Nasdaq: UPWK), the world’s largest work marketplace that connects businesses with independent talent from across the globe, today announced its financial results for the third quarter of 2023. Please visit the Upwork Investo...
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- CarGurus (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, buying, and selling new and used vehicles 1 , today announced it has entered into a definitive agreement to acquire the remaining minority equity interest...
Revenue of $167.3 million for the quarter, an increase of 8% year-over-year Subscription revenue of $104.5 million for the quarter, an increase of 14% year-over-year $212.1 million of cash and cash equivalents and no debt outstand...
Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 20...
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand t...
Received 430 new patient start forms for FILSPARI ® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI totaled $8 million for the third quarter of 2023 Phase 3 PROTECT and DUPLEX Studies of sparsent...
Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit margin of 76% versus 67% for the third quarter 2022 and 73% for the second quarter of 2023; Net loss, which includes certa...
OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD Population Delta at 6 and 12-month AHV Between Optimal LUM-201 Dose of 1.6 mg/kg and rhGH Compa...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
22.91%Change Percent:
SmartRent Inc. Class A Company Name:
SMRT Stock Symbol:
NYSE Market:
smartrent.com Website: